Immunocore's sole marketed drug Kimmtrak generated $400 million in 2025 sales, but the company's next act hinges on pivotal trial results due in the second half of 2026.
Quay lại
Immunocore's Kimmtrak sales climb 29% as 2026 trial catalysts loom
Immunocore's sole marketed drug Kimmtrak generated $400 million in 2025 sales, but the company's next act hinges on pivotal trial results due in the second half of 2026.
Immunocore Holdings Plc's Kimmtrak, a first-in-class bispecific T-cell engager designed to redirect T cells toward cancer cells expressing the gp100 antigen, generated $400 million in 2025 sales — a 29 percent increase from the prior year. The growth reflects continued adoption since the drug's 2022 approval for HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma, a rare eye cancer with historically limited treatment options.
The five-year follow-up data from the pivotal phase III trial, presented in April 2026, showed a 16 percent overall survival rate with Kimmtrak compared with 8 percent for the control arm, according to the company. Median overall survival reached 21.6 months with Kimmtrak versus 16.9 months for investigator's choice, strengthening the drug's first-line positioning in eligible patients. The durability record may support physician confidence in a disease where five-year survival has traditionally been below 10 percent.
Kimmtrak is approved in 39 countries and launched in more than 30, with adoption driven by higher volumes in the United States and Europe, broader reimbursement coverage and continued geographic expansion. The drug's mechanism of action — a bispecific protein that binds both the T-cell receptor and the tumor antigen — differentiates it from checkpoint inhibitors that work by releasing existing immune brakes rather than redirecting immune cells.
The TEBE-AM Readout Could Reshape the Melanoma Landscape
The most significant near-term catalyst is the phase III TEBE-AM study, testing Kimmtrak as monotherapy and in combination with standard-of-care checkpoint inhibitors in advanced cutaneous melanoma after prior anti-PD-(L)1 treatment. Top-line results are expected as early as the second half of 2026.
No therapy has shown an overall survival benefit after checkpoint inhibitor treatment in a randomized study in this setting, making a positive readout potentially practice-changing. Bristol Myers Squibb Co., through Opdivo, and Merck & Co. Inc., through Keytruda, dominate the checkpoint inhibitor market, giving Immunocore's post-checkpoint strategy a clear competitive frame. A positive result would position Kimmtrak in a much larger patient population than its current uveal melanoma indication, which affects roughly 2,000 to 3,000 patients annually in the United States.
Adjuvant Opportunity Remains Years Away
Immunocore is also evaluating Kimmtrak as an adjuvant therapy for uveal melanoma in the registrational phase III ATOM study, led by the European Organisation for Research and Treatment of Cancer. Moving into an earlier treatment setting could expand the drug's addressable market beyond metastatic disease, though enrollment is not expected to be completed until 2028, with data likely several years after that.
Immunocore remains a single-product company, with Kimmtrak accounting for all of its revenue. The TEBE-AM readout represents the most immediate opportunity to diversify beyond uveal melanoma — and the most binary risk for investors. If positive, the drug could address a multi-billion-dollar market currently dominated by checkpoint inhibitors. If negative, the company's growth narrative would revert to the slow-and-steady expansion of a niche orphan drug.
This article is for informational purposes only and does not constitute investment advice.
